公开(公告)号：US20100008855A1

公开(公告)日：2010-01-14

申请号：US12474665

申请日：2009-05-29

Applicant: David M. Goldenberg ,  Hans J. Hansen ,  William J. McBride

Inventor： David M. Goldenberg ,  Hans J. Hansen ,  William J. McBride

IPC: A61K49/00 ,  A61K39/395 ,  A61K51/08 ,  A61K49/22 ,  A61K38/18 ,  A61K33/22 ,  A61K38/43 ,  A61K38/20 ,  A61K38/21 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/519

CPC classification number: A61K51/1048 ,  A61K47/665 ,  A61K47/6879 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/0215 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

Abstract translation: 本发明涉及具有特异性结合目标组织的至少一个臂的特异性抗体或抗体片段以及特异性结合可靶向构建体的至少一个其他臂。 可靶向构建体包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向构建物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。

公开(公告)号：US20090324723A1

公开(公告)日：2009-12-31

申请号：US10992478

申请日：2004-11-19

Applicant: Grant Thomas Rawlin ,  Gottfried Lichti ,  Roy Michael Robins-Browne ,  Brian David Muller

Inventor： Grant Thomas Rawlin ,  Gottfried Lichti ,  Roy Michael Robins-Browne ,  Brian David Muller

IPC: A61K9/14 ,  A61K39/40 ,  A61K9/12 ,  A61P11/00 ,  A61P37/04

CPC classification number: A61K9/0075 ,  A61K9/008 ,  A61K2039/505 ,  C07K16/1228 ,  C07K16/1278 ,  C07K2317/12 ,  C07K2317/54 ,  Y02A50/478

Abstract: A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said bacteria which survives inside phagocytes. The binding proteins comprise antibodies or antibody fragments directed against said bacteria which survives inside phagocytes. The binding proteins are selected from the group consisting of polyclonal antibodies, monoclonal antibodies, F(ab) fragments, F(ab′)2 fragments, antibody tip fragments, chimeric and humanized antibodies and fragments and recombinant antibodies and fragments.

Abstract translation: 一种通过致病性空气传播细菌预防受试者呼吸道感染的方法，该方法包括通过吸入结合针对细菌的蛋白质对受试者施用。 致病细菌是在吞噬细胞内存活的细菌，并且结合蛋白被针对在吞噬细胞内存活的所述细菌。 结合蛋白包含针对在吞噬细胞内存活的所述细菌的抗体或抗体片段。 结合蛋白选自多克隆抗体，单克隆抗体，F（ab）片段，F（ab'）2片段，抗体末端片段，嵌合和人源化抗体及片段以及重组抗体和片段。

公开(公告)号：US20090263864A1

公开(公告)日：2009-10-22

申请号：US12221021

申请日：2008-07-29

Applicant: Patrick H. C. Van Berkel ,  Ronald Hendrik Peter Brus ,  Ton Logtenberg ,  Abraham Bout

Inventor： Patrick H. C. Van Berkel ,  Ronald Hendrik Peter Brus ,  Ton Logtenberg ,  Abraham Bout

IPC: C12P21/08 ,  C12N15/87

CPC classification number: C12P21/005 ,  A61K39/39558 ,  C07K16/00 ,  C07K16/10 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/12 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/50 ,  C07K2317/51 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2319/30 ,  Y02P20/582

Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.

Abstract translation: 本发明提供从单个宿主细胞克隆产生抗体混合物的方法，其中编码轻链的核酸序列和编码不同重链的核酸序列在重组宿主细胞中表达。 根据本发明的混合物中重组产生的抗体适当地包含与能够与轻链配对的不同重链配对的相同的轻链，从而形成功能性抗原结合结构域。 重组产生的抗体的混合物也由本发明提供。 这种混合物可用于各种领域。

公开(公告)号：US07560110B2

公开(公告)日：2009-07-14

申请号：US11198846

申请日：2005-08-08

Applicant: David M. Goldenberg ,  Hans J. Hansen ,  William J. McBride

Inventor： David M. Goldenberg ,  Hans J. Hansen ,  William J. McBride

IPC: A61K39/395

CPC classification number: A61K51/1048 ,  A61K47/665 ,  A61K47/6879 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/0215 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

Abstract translation: 本发明涉及具有特异性结合目标组织的至少一个臂的特异性抗体或抗体片段以及特异性结合可靶向构建体的至少一个其他臂。 可靶向构建体包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向构建物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。

公开(公告)号：US07553953B2

公开(公告)日：2009-06-30

申请号：US12042063

申请日：2008-03-04

Applicant: Hans J. Hansen ,  David M. Goldenberg

Inventor： Hans J. Hansen ,  David M. Goldenberg

IPC: A61K39/395 ,  C07H21/04

CPC classification number: C07K16/3076 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6863 ,  A61K47/6879 ,  A61K47/6897 ,  A61K51/1045 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/3092 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00 ,  Y10S436/813 ,  Y10S436/819

Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.

Abstract translation: 本发明提供可用于治疗和诊断包括结肠癌在内的各种癌症的人源化，嵌合和人抗CSAp抗体和抗CSAp抗体融合蛋白。

公开(公告)号：US20090165154A1

公开(公告)日：2009-06-25

申请号：US12231873

申请日：2008-09-05

Applicant: James M. Robl ,  Yoshimi Kuroiwa ,  Kazuma Tomizuka ,  Isao Ishida

Inventor： James M. Robl ,  Yoshimi Kuroiwa ,  Kazuma Tomizuka ,  Isao Ishida

IPC: C12N15/87 ,  A01K67/027 ,  C12N5/06

CPC classification number: C12N15/8509 ,  A01K67/0271 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2227/101 ,  A01K2267/01 ,  A01K2267/02 ,  C07K16/00 ,  C07K2317/12 ,  C07K2317/21 ,  C12N2800/30

Abstract: The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and a safer source of agricultural products.

Abstract translation: 本发明提供克隆的转基因有蹄类动物（例如牛），其中朊蛋白活性被一种或多种遗传工程改造的突变所减少。 理想地，这些转基因牛也被遗传修饰以表达异种（例如人）抗体。 由于它们对诸如牛海绵状脑病（也称为疯牛病）的朊病毒相关疾病的抵抗力，这些牛奶是用于制药用途和更安全的农产品源的人类抗体的更安全来源。

公开(公告)号：US07429690B2

公开(公告)日：2008-09-30

申请号：US10705519

申请日：2003-11-10

Applicant: James M. Robl ,  Yoshimi Kuroiwa ,  Kazuma Tomizuka ,  Isao Ishida

Inventor： James M. Robl ,  Yoshimi Kuroiwa ,  Kazuma Tomizuka ,  Isao Ishida

IPC: A01K67/027 ,  C12N15/00 ,  C12N5/00

CPC classification number: C12N15/8509 ,  A01K67/0271 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2227/101 ,  A01K2267/01 ,  A01K2267/02 ,  C07K16/00 ,  C07K2317/12 ,  C07K2317/21 ,  C12N2800/30

Abstract: The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and a safer source of agricultural products.

Abstract translation: 本发明提供克隆的转基因有蹄类动物（例如牛），其中朊蛋白活性被一种或多种遗传工程改造的突变所减少。 理想地，这些转基因牛也被遗传修饰以表达异种（例如人）抗体。 由于它们对诸如牛海绵状脑病（也称为疯牛病）的朊病毒相关疾病的抵抗力，这些牛奶是用于制药用途和更安全的农产品来源的人类抗体的更安全来源。

公开(公告)号：US07429381B2

公开(公告)日：2008-09-30

申请号：US11216033

申请日：2005-09-01

Applicant: Hans J. Hansen ,  Gary L. Griffiths ,  Shui-on Leung ,  William J. McBride ,  Zhengxing Qu

Inventor： Hans J. Hansen ,  Gary L. Griffiths ,  Shui-on Leung ,  William J. McBride ,  Zhengxing Qu

IPC: A61K39/395 ,  A61K39/40 ,  A61K39/42

CPC classification number: C07K16/468 ,  A61K47/6863 ,  A61K47/6899 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.

Abstract translation: 本发明涉及一种双特异性抗体或抗体片段，其具有至少一个对靶组织有反应性的臂，以及至少一个对接头部分具有反应性的其它臂。 接头部分包括已经制备抗体的半抗原。 抗原性接头与一种或多种治疗剂或诊断剂或酶缀合。 本发明提供了用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。

公开(公告)号：US07414121B2

公开(公告)日：2008-08-19

申请号：US11070697

申请日：2005-03-03

Applicant: Hans J. Hansen ,  David M. Goldenberg

Inventor： Hans J. Hansen ,  David M. Goldenberg

IPC: C12N15/13

CPC classification number: C07K16/3076 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6863 ,  A61K47/6879 ,  A61K47/6897 ,  A61K51/1045 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/3092 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00 ,  Y10S436/813 ,  Y10S436/819

Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusio proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.

Abstract translation: 本发明提供可用于治疗和诊断包括结肠癌在内的各种癌症的人源化，嵌合和人抗CSAp抗体和抗CSAp抗体融合蛋白。

公开(公告)号：US20080089838A1

公开(公告)日：2008-04-17

申请号：US11928775

申请日：2007-10-30

Applicant: Hans Hansen ,  David Goldenberg

Inventor： Hans Hansen ,  David Goldenberg

IPC: A61K33/24 ,  A61K33/22 ,  A61K38/43 ,  A61K39/00 ,  A61K39/395 ,  A61K49/00 ,  A61K51/00 ,  A61P37/00 ,  C07H21/04

CPC classification number: C07K16/3076 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6863 ,  A61K47/6879 ,  A61K47/6897 ,  A61K51/1045 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/3092 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00 ,  Y10S436/813 ,  Y10S436/819

Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.